Biogen's S1P Modulator License – A Good Deal Done Too Late?
This article was originally published in Scrip
Biogen's license for the sphingosine 1-phosphate (S1P) receptor modulator MT-1303 from Mitsubishi Tanabe for up to $544m makes a lot of sense, but with four S1P-targeting drugs approved or in late-stage development did Biogen execute a good deal too late to catch up with the competition?
You may also be interested in...
The first round of third-quarter earnings reports for big pharmas quietly featured news about drug discontinuations and failures.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.